Publications:

---

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.

Cancer Medicine

Liu, Binliang B; Yi, Zongbi Z; Guan, Yanfang Y; Ouyang, Quchang Q; Li, Chunxiao C; Guan, Xiuwen X; Lv, Dan D; Li, Lixi L; Zhai, Jingtong J; Qian, Haili H; Xu, Binghe B; Ma, Fei F; Zeng, Yixin Y

Publication Date: 2022-07

Variant appearance in text: ERBB2: 3482G>A; R1161Q

PubMed Link: 35393784

Variant Present in the following documents:

• CAM4-11-2767-s001.xlsx, sheet 1

View BVdb publication page

---

Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms.

Cancers

Braunstein, Evan M EM; Chen, Hang H; Juarez, Felicia F; Yang, Fanghan F; Tao, Lindsay L; Makhlin, Igor I; Williams, Donna M DM; Chaturvedi, Shruti S; Pallavajjala, Aparna A; Karantanos, Theodoros T; Martin, Renan R; Wohler, Elizabeth E; Sobreira, Nara N; Gocke, Christopher D CD; Moliterno, Alison R AR

Publication Date: 2021-06-29

Variant appearance in text: ERBB2: R1161Q

PubMed Link: 34209587

Variant Present in the following documents:

• Main text
• cancers-13-03246.pdf

View BVdb publication page

---

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.

Npj Breast Cancer

Yi, Zongbi Z; Rong, Guohua G; Guan, Yanfang Y; Li, Jin J; Chang, Lianpeng L; Li, Hui H; Liu, Binliang B; Wang, Wenna W; Guan, Xiuwen X; Ouyang, Quchang Q; Li, Lixi L; Zhai, Jingtong J; Li, Chunxiao C; Li, Lifeng L; Xia, Xuefeng X; Yang, Ling L; Qian, Haili H; Yi, Xin X; Xu, Binghe B; Ma, Fei F

Publication Date: 2020

Variant appearance in text: ERBB2: 3482G>A; R1161Q

PubMed Link: 33145402

Variant Present in the following documents:

• 41523_2020_201_MOESM2_ESM.xlsx, sheet 1

View BVdb publication page

---

LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype.

Frontiers In Oncology

Cao, Canhui C; Lin, Shitong S; Zhi, Wenhua W; Lazare, Cordelle C; Meng, Yifan Y; Wu, Ping P; Gao, Peipei P; Wei, Juncheng J; Wu, Peng P

Publication Date: 2020

Variant appearance in text: ERBB2: R1161Q

PubMed Link: 32211324

Variant Present in the following documents:

• Table_1.xls, sheet 6

View BVdb publication page

---

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.

Oncotarget

Hutchinson, Katherine E KE; Johnson, Douglas B DB; Johnson, Adam S AS; Sanchez, Violeta V; Kuba, Maria M; Lu, Pengcheng P; Chen, Xi X; Kelley, Mark C MC; Wang, Qingguo Q; Zhao, Zhongming Z; Kris, Mark M; Berger, Michael F MF; Sosman, Jeffrey A JA; Pao, William W

Publication Date: 2015-09-08

Variant appearance in text: ERBB2: R1161Q

PubMed Link: 26084293

Variant Present in the following documents:

• oncotarget-06-22348-s003.xlsx, sheet 1

View BVdb publication page

---

Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.

Plos One

Bodian, Dale L DL; McCutcheon, Justine N JN; Kothiyal, Prachi P; Huddleston, Kathi C KC; Iyer, Ramaswamy K RK; Vockley, Joseph G JG; Niederhuber, John E JE

Publication Date: 2014

Variant appearance in text: ERBB2: R1161Q; rs150680317

PubMed Link: 24728327

Variant Present in the following documents:

• pone.0094554.s002.xlsx, sheet 1

View BVdb publication page

---